- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02850978
Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
November 15, 2019 updated by: Boehringer Ingelheim
Post-marketing Surveillance (PMS) on Long-term Use of Tiotropium+Olodaterol Fixed Dose Combination (Tio+Olo FDC) 5µg/5µg in Patients With Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) in Japan
Study to assess the long-term safety and effectiveness of Spiolto in Japanese patients with Chronic Obstructive Pulmonary Disease (COPD) in real-world setting
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
1335
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Multiple Locations, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
1000
Description
Inclusion criteria:
- Patients who have been diagnosed with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) by physician and need relief of various symptoms associated with Long Acting Beta2 Agonist (LABA) or Long Acting Muscarinic Antagonist (LAMA).
- Patients who are prescribed Tio+Olo FDC 5µg/5µg for the first time
Exclusion criteria:
- Patients who have been registered once in this study (i.e., re-entry of patients is not allowed).
- Patients who are participating in a registry or clinical trial.
- Patients who have a contraindication to Tio+Olo FDC 5µg/5µg defined in the package insert for Tio+Olo FDC 5µg/5µg.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Spiolto
Patient with COPD to received Spiolto
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Adverse Drug Reactions
Time Frame: From the first drug administration until 21 days after the last drug administration, up to approximately 82 weeks.
|
Percentage of participants with adverse drug reactions (ADR).
An adverse drug reaction (ADR) is defined as an adverse event (AE) for which either the investigator or the sponsor (or both) assess the causal relationship to Spiolto® Respimat® as "Yes".
|
From the first drug administration until 21 days after the last drug administration, up to approximately 82 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of COPD Assessment Test (CAT) Score From Baseline to Week 12
Time Frame: Baseline and Week 12
|
The COPD Assessment Test™ (CAT) is a short 8-item questionnaire for assessment and monitoring of COPD health status in routine practice.
Its scale is 0-40 (high score = poor health).
The CAT questionnaire has the advantage of a reduced number of items and could be used to assess the effects of inhaled therapies.
The CAT score was the sum of the values corresponding to the answers to the eight questions.
|
Baseline and Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
August 23, 2016
Primary Completion (ACTUAL)
October 30, 2018
Study Completion (ACTUAL)
November 30, 2018
Study Registration Dates
First Submitted
July 28, 2016
First Submitted That Met QC Criteria
July 28, 2016
First Posted (ESTIMATE)
August 1, 2016
Study Record Updates
Last Update Posted (ACTUAL)
December 6, 2019
Last Update Submitted That Met QC Criteria
November 15, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1237.34
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Spiolto
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveGermany
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveItaly
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimTerminatedAssessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)Pulmonary Disease, Chronic ObstructiveBelgium, Luxembourg, Netherlands, Denmark, Portugal, Sweden
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveIsrael, Russian Federation, Ukraine, Bulgaria, Czechia, Hungary, Lithuania, Poland, Romania, Slovenia, Switzerland
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveGermany
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveDenmark, Netherlands, Finland, Belgium, Germany, Norway
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveChina
-
Boehringer IngelheimCompleted